

Antibody Response to a Nucleocapsid Epitope as a Marker for COVID-19 Disease Severity

Authors:

Sanjana Sen^{1†}, Emily C. Sanders^{2†}, Kristin N. Gabriel^{1†}, Brian M. Miller², Hariny M. Isoda², Gabriela S. Salcedo², Jason E. Garrido¹, Rebekah P. Dyer¹, Rie Nakajima³, Aarti Jain³, Alicia M. Santos², Keertna Bhuvan², Delia F. Tifrea⁴, Joni L. Ricks-Oddie^{5,6}, Philip L. Felgner³, Robert A. Edwards⁴, Sudipta Majumdar², and Gregory A. Weiss^{1,2,7*}

Affiliations:

¹ Department of Molecular Biology & Biochemistry, University of California, Irvine, Irvine CA 92697-3900 USA

² Department of Chemistry, University of California, Irvine, Irvine CA 92697-2025 USA

³ Department of Physiology and Biophysics, University of California, Irvine, Irvine CA 92697-4560 USA

⁴ Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine CA 92697-4800 USA

⁵ Center for Statistical Consulting, Department of Statistics, University of California, Irvine, Irvine CA 92697-1250 USA

⁶ Biostatistics, Epidemiology and Research Design Unit, Institute for Clinical and Translational Sciences, University of California, Irvine, Irvine CA 92697-4094 USA

⁷ Department of Pharmaceutical Sciences, University of California, Irvine, Irvine CA 92697-3958 USA

[†] These authors contributed equally.

* Address correspondence to gweiss@uci.edu

Short Title:

Antibody basis for COVID-19 severity

One Sentence Summary:

Antibodies targeting a specific location within a SARS-CoV-2 structural protein are linked to poor COVID-19 disease outcomes.

Abstract:

Characterization of antibody response to SARS-CoV-2 is urgently needed to predict COVID-19 disease trajectories. Ineffective antibodies or antibody-dependent enhancement (ADE) could derail patients' immune responses, for example. ELISA and coronavirus antigen microarray (COVAM) analysis epitope-mapped plasma from 86 COVID-19 patients. The experiments identified antibodies to a 21-residue epitope from nucleocapsid (termed Ep9) associated with severe disease, including ICU stay, requirement for ventilators, and death. Furthermore, anti-Ep9 antibodies correlate both with various comorbidities and ADE hallmarks, including increased IL-6 levels and early IgG response. Importantly, anti-Ep9 antibodies can be detected within five days post-symptom onset and sometimes within one day. The results lay the groundwork for a new type of COVID-19 diagnostic for the early prediction of disease severity to guide more effective therapeutic interventions.

Main Text:

The COVID-19 pandemic has triggered an ongoing global health crisis. More than 37 million confirmed cases and 1 million deaths have been reported worldwide as of October 12, 2020 (1). The virus that causes COVID-19, severe acute respiratory syndrome coronavirus (SARS-CoV-2), belongs to the same family of viruses responsible for respiratory illness linked to recent epidemics – severe acute respiratory syndrome (SARS) in 2002-2003 and Middle East respiratory syndrome (MERS) in 2012 (2). The current and previous outbreaks suggest coronaviruses will remain viruses of concern for global health.

Many risk factors and comorbidities, including, age, sex, and medical history, including hypertension, diabetes, and obesity, influence COVID-19 patient prognosis (3). Analysis of patient immune parameters has linked disease severity to elevated levels of biomarkers for inflammation (c-reactive protein and cardiac troponin I), organ damage (aspartate aminotransferase, abbreviated AST, and hypoalbuminemia), immune hyperactivity (IL-6 and IL-10), and clotting (D-dimer) (4). Mortality in COVID-19 is often caused by multi-organ injury and severe pneumonia attributed to an overzealous immune response, called a cytokine storm (5). Given the rapid COVID-19 disease progression and no proven curative treatment, a better understanding of the antibody response is urgently needed to potentially predict disease trajectories and guide interventions.

Vast differences in the severity of COVID-19 from asymptomatic to death remain an enduring puzzle. One hypothesis to explain these differences implicates weakly binding, non-neutralizing antibodies (Abs) to SARS-CoV-2 proteins. Such Abs could cause antibody-dependent enhancement (ADE) of COVID-19, through antibody-

facilitated viral infection or enhanced immune activation (6). In addition to understanding and predicting disease trajectories, characterization of ADE could ensure patient safety during development of antibody-based vaccines and therapeutics. ADE has been observed for multiple viruses, including respiratory syncytial virus (RSV); poorly neutralizing Abs generated in response to RSV vaccination can enhance complement immune activation and disease severity in patients (7). Though *in vitro* and *in vivo* animal studies demonstrate enhanced immunopathology upon antibody challenge in SARS and MERS, ADE remains ill-defined in SARS-CoV-2 (6, 8). Furthermore, a recent overview of ADE in COVID-19 stated, “At present, there are no known clinical findings, immunological assays or biomarkers that can differentiate any severe infection from immune-enhanced disease, whether by measuring antibodies, T cells or intrinsic host responses (8).” This conclusion motivated our study.

SARS-CoV-2 encodes four major structural proteins – spike (S), nucleocapsid (N), membrane (M), and envelope (E). The S, N, and M proteins from SARS elicit an Ab-based immune response (9, 10), whereas the Ab response against these structural proteins from SARS-CoV-2 remains under investigation (11). Bioinformatics has predicted >55 Ab binding epitopes from SARS-CoV-2 (12–17). However, the role antibodies against such epitopes play in disease progression remains ill-defined. Additionally, the epitopes for N, M or E proteins are less well-characterized than for S protein. Illustrating their potential importance, Abs to N protein in SARS patients elicit a highly immunogenic, long-lasting response (18). To characterize epitopes from SARS-CoV-2, ELISAs with phage-displayed epitopes (phage ELISAs) and coronavirus antigen microarray (COVAM) analysis (19) examined plasma samples from COVID-19 patients (n = 86). As shown

here, correlation of Abs to an epitope from N protein with patient outcomes demonstrates the importance of fine epitope mapping.

Results

Design and production of candidate epitopes

Twenty-two putative SARS-CoV-2 epitopes were predicted through bioinformatics (12–14) and structure-based analysis. The candidate epitopes span the S, N, M, or E proteins and are 15 to 211 amino acids in length (**Fig. 1** and **Table S1**). The structure of S protein bound to a neutralizing antibody (20, 21) provided the starting point for 13 of these antibody epitopes. After display of each potential epitope on the surface of phage, the quality of the epitopes was evaluated by PCR, DNA sequencing, and QC ELISA (**Fig. S1**). A total of 18 phage-displayed, putative epitopes passed quality control, and were selected for further study.




Fig. 1. Predicted SARS-CoV-2 epitopes examined by phage ELISA. Structural models (gray) of the SARS-CoV-2 **A**) S, **B**) N, **C**) M, or **D**) E proteins illustrate our epitope design (colored). These epitopes were phage-displayed, which could result in loss of their 3D structures. The depicted structural models were derived from an S protein X-ray structure (PDB: 6VXX) (20) or computation modeling of N, M, and E proteins (Protein Gene Bank:

QHD43423, QHD43419, and QHD43418, respectively) (22). **Table S1** provides sequences and where applicable sources of each epitope.

Mapping epitope binding to anti-SARS-CoV-2 Abs

Plasma from COVID-19 patients was subjected to ELISAs with the phage-displayed SARS-CoV-2 epitopes (**Fig. 2A**). Unless otherwise indicated, plasma refers to samples from PCR-verified, COVID-19 patients. In this initial assay, plasma was pooled, diluted 100-fold, and coated on a microtiter plate (3 pools of $n = 5$ patients per pool). Nonspecific interactions were blocked (ChonBlock), and phage-displayed epitopes were added for ELISA. The resultant data were normalized by signal from the corresponding negative control (phage without a displayed epitope). Seven promising epitopes from the pooled patients were further investigated with a larger number of individual patient samples ($n = 28$) (**Fig. 2B**). The strongest binding was observed for three epitopes from M (Ep6), N (Ep9), and S (Ep21) proteins. Additional COVID-19 plasma samples were profiled for binding to these three epitopes ($n = 86$ total) (**Fig. 2B**).

The Ep9 epitope from N protein demonstrated robust antibody binding in 27% of the patient plasmas ($n = 86$). The other epitopes either failed to produce statistically sufficient numbers of responses, or, despite sufficient numbers, lacked clinical data demonstrating correlation with disease severity. Levels of anti-Ep9 Abs (α Ep9 Abs) were mapped over 43 days. The highest levels of α Ep9 Abs were observed at days 1 to 14 post-symptom onset ($n = 11$) with peaks for most patients appearing within days 4 to 9 (**Fig. 2C**).




Fig. 2. Mapping COVID-19 patient antibody responses with phage-displayed SARS-CoV-2 epitopes. **A)** This phage ELISA with the indicated epitopes (x-axis) examined plasma pooled from patients (n = 3 pools of 5 patients each, 2 technical replicates). **B)** The epitopes with the highest signals were then further examined by ELISA with plasma from individual patients (n as indicated). **C)** With samples from individual patients (designated as P# and by color) collected at the indicated times, changing levels of Ep9 were characterized. **D)** Ep9 orthologs from SARS, MERS, HKU-1, or NL63 (x-axis) examined the cross-reactivity of Abs to Ep9 (3 technical replicates). Error bars represent SEM (panels A, B, and D) or range of two measurements (panel C).

Cross-reactivity of α Ep9 Abs against orthologous epitopes from other coronaviruses

Next, the cross-reactivity of α Ep9 Abs was examined with Ep9-orthologs from four phylogenetically related coronaviruses known to infect humans (**Fig. S2A**). Specifically, plasma with α Ep9 Abs (n = 3 patients) and pooled plasma from healthy individuals (n = 5) were assayed. The Ep9 epitopes from SARS-CoV-2 and SARS have 90% amino acid sequence homology. Unsurprisingly, this high degree of similarity resulted in a cross-reactive Ep9 epitope, and a strong antibody response was observed to Ep9 epitopes from

both viruses (**Fig. 2D**). In contrast, more distantly related orthologs exhibited no cross-reactivity with the α Ep9 Abs. The coronaviruses, MERS, HKU-1, and NL63 have 52%, 43%, and 8% sequence homology to SARS-CoV-2 Ep9, respectively (**Fig. S2B**). Furthermore, no response was observed to the Ep9 epitopes in pooled plasma from healthy patients.

COVAM analysis tests cross-reactivity with a panel of 61 antigens from 23 strains of 10 respiratory tract infection-causing viruses. In this assay, each antigen was printed onto microarrays, probed with human sera or plasma, and analyzed as previously described. COVAM distinguishes between IgG and IgM Abs binding to the full-length N protein (**Fig. S3** and **S4**, respectively). The ELISA and COVAM data both demonstrate that α Ep9 Abs are highly specific for lineage B betacoronaviruses, and unlikely to be found in patients before their infection with SARS-CoV-2.

More severe disease and poorer outcomes for α Ep9 patients

Direct comparison of the data from COVAM and ELISA (n = 40 patients assayed with both techniques) reveals five unique categories of patients. The raw data from each assay was normalized as a percentage of the negative control (**Fig. 3A**). The first category consisted of patients without antibodies to the N protein. The next categories (2 and 3) included patients with IgM or IgG Abs, respectively, whose Abs bound to N protein, but not the Ep9 epitope; such Abs are termed non-Ep9 α N Abs. The final categories identify patients with either both IgM and IgG α Ep9 Abs or exclusively IgG α Ep9 Abs (4 and 5, respectively). The α Ep9 Abs are only found in patients with IgM or IgGs against N protein

from the COVAM assay, which thus independently corroborates the ELISA results (**Figs. 2A-C**).

Interestingly, the patients with α Ep9 Abs in our study suffer more prolonged illness and worse clinical outcomes compared to patients with non-Ep9 α N Abs or no α N Abs. Specifically, the fraction of severe COVID-19 cases (e.g., ICU, intubation, or death) was 2.5 times higher in patients with α Ep9 Abs than non-Ep9 α N Abs patients (**Fig. 3B, yellow panel**); the differences in proportions of severe and non-severe α N-positive patients having and lacking α Ep9 are statically significant ($p < 0.0298$, Fisher's exact test). Patients without α N Abs had less severe symptoms. The α Ep9 Abs patients also had longer durations of symptoms and hospital stays relative to non-Ep9 α N Abs and no α N Abs patients (**Figs. 3C and D**). A larger data set of patient plasma analyzed by phage ELISA confirmed this conclusion ($p < 0.0013$, Fisher's exact test) (**Fig. 3B, blue panel**). Our data further demonstrates that asymptomatic COVID-19 patients ($n = 3$) also tested negative for α Ep9 Abs (**Table S2**). The COVAM/ELISA comparison also reveals early seroconversion in patients with α Ep9 IgGs (**Fig. 3E**), but not α Ep9 IgMs (**Fig. 3F**).




Fig. 3. Patients with αEp9 Abs have more severe disease. **A)** Normalized and categorized data from measurements by COVAM (IgMs in yellow, IgGs in green) and αEp9 phage ELISA (blue). ANOVA comparing COVAM to ELISA with Dunnett's multiple comparisons yields p-values of **<0.01, ****<0.0001, or ns: not significant. **B)** Disease severity (color) binned by antibody response (COVAM in yellow, or ELISA in blue). Statistical analysis reveals significant differences between distributions of severe and non-severe disease comparing patient categories, $p < 0.01$ (χ^2) and $p < 0.001$ (Fisher's exact test) for COVAM and ELISA, respectively. Patients with αEp9 Abs are **C)** symptomatic for longer durations and **D)** spend more days in the hospital than those with other αN Abs or no αN Abs. ANOVA with Tukey's multiple comparisons yields p-values of *<0.05 and **<0.01. One outlier (black) (ROUT = 0.1%) was omitted from statistical calculations for panels C and D. **E)** The αN IgG appear at high levels early in the course of disease only for αEp9-positive patients, but are lower in non-Ep9, αN-positive patients. After >15 days post symptom onset, αN IgG levels increase for both groups of patients. **F)** However, IgM levels do not change significantly. Error bars depict SEM with the indicated number of patients (n, numbers above columns).

Strong correlation between disease severity and comorbidities in patients with αEp9 Abs

We compared risk factors, clinical parameters, and disease outcomes among patients with αEp9 Abs (n = 22) (**Figs. 4A and S5**). A *disease risk factor score* (DRFS) was developed to evaluate the relationship between clinical preconditions and disease

severity in patients with α Ep9 Abs. The DRFS quantifies a patient's age, sex, and pre-existing health conditions associated with COVID-19 disease severity and mortality, including hypertension, diabetes, obesity, cancer, chronic cardiac, kidney, and pulmonary disease (23–25). Using the *age score* from the Charlson Comorbidity Index (26) yields a patient's DRFS as:

$$DRFS = \Sigma (\# \text{ of risk factors}) + (\text{age score})$$

where risk factors are valued as 0 or 1 if absent or present, respectively. The DRFS of patients with α Ep9 Abs strongly correlate with COVID-19 disease severity (Pearson's $r = 0.7499$, $p\text{-value} < 0.0001$, and $R^2 = 0.05623$) (**Fig. 4A**). The correlation in patients without α Ep9 Abs is very weak ($r = 0.272$, $p\text{-value} = 0.0255$, $R^2 = 0.0755$) (**Fig. 4A**).

The presence of α Ep9 Abs correlates with more severe disease in patients who have hypertension, diabetes, or age > 50 years. Such correlation is not observed for patients lacking α Ep9 Abs (**Figs. 4B**). Notably, such risk factors are prevalent at roughly the same percentages in both populations of patients (**Table S2**). Thus, these risk factors are particularly acute for patients with α Ep9 Abs.




Fig. 4. Correlation between disease severity and risk factors in patients with α Ep9 Abs. **A)** The relationship between DRFS and disease severity of COVID-19 patients with α Ep9 Abs (blue) or no α Ep9 Abs (gray). Each data point represents one patient. The solid lines indicate linear regression fits with 95% confidence intervals (dotted lines), and Pearson's r -value. **B)** The color-indicated risk factors (diabetes, hypertension, and age >50 years) are depicted on the x-axis as the fractions of patients in each disease severity category (y-axis). Numbers indicate total patients (n) with no α Ep9 Abs (left) or α Ep9 Abs (right). The prevalence of risk factors (colors) increases with disease severity in patients with α Ep9 Abs, but not in patients lacking these Abs.

High levels of inflammatory cytokine and tissue damage markers in patients with α Ep9 Abs

COVID-19 patients can have elevated serum concentrations of >20 inflammatory cytokines and chemokines (27). However, information on the cytokine levels and the association with tissue damage and worse COVID-19 outcomes have been inconsistent (27–29). For patients with IL-6 concentrations measured in plasma, patients with ($n = 8$)

or without ($n = 11$) α Ep9 Abs were compared. Interestingly, we uncovered a strong positive sigmoidal association between IL-6 and AST unique to patients with α Ep9 Abs ($R^2 = 0.9683$, Spearman's $r = 1.0$, p -value < 0.0001 , $n=8$) (Blue line, **Fig. S6A**); correlation of IL-6 and AST in patients with α Ep9 Abs remains strong even after removal of the data point at the highest IL-6 concentration. No significant correlation is observed in patients lacking α Ep9 Abs (Spearman's $r = -0.5748$, p -value $= 0.0612$, $n=13$). Thus, the presence of α Ep9 Abs can disambiguate the sometimes contradictory levels of IL-6 associated with disease severity.

Discussion

This report introduces α Ep9 Abs as a marker for COVID-19 disease severity and its worst outcomes. Previously, anti-SARS-CoV-2 Abs, particularly IgGs against N and S proteins, have been associated with disease severity and poor outcomes (30–32). Several studies recognize the RNA binding domain of N protein, which includes Ep9, as a focal site for antibody response. For example, phage display-based VirScan identified three α N Ab epitopes spanning residues 141-196 (33), 142-208 and 209-265 (34), and analysis by ReScan microarrays isolated four α N Ab epitopes – residues 134-171 and 153-190 (34). However, correlation between these epitopes and disease severity has not been found.

Notably, we examine shorter peptide epitopes (e.g., 21 residues from 152-172 for Ep9) than previous studies (**Table S1**). Short peptides can more finely hone differences in antigen recognition and potentially antibody efficacy. The finer epitope mapping of the present study demonstrates that not all α N Abs link to disease severity. Additionally, a

wider range of disease conditions from asymptomatic to fatal can be examined from our patient population.

We hypothesize that the underlying mechanism relating α Ep9 Abs to increased disease severity involves ADE of immune activation. Supporting this hypothesis, the hallmarks of ADE appear in patients with α Ep9 Abs. These include early seroconversion and strong upregulation of IgGs (**Fig. 3E**), which have been correlated with low viral clearance in patients and increased COVID-19 severity (30, 35). The early upregulation of α Ep9 IgGs could indicate their poor virus neutralization. Also ADE-associated (36, 37), high levels of IL-6 are observed for α Ep9-positive patients with increased levels of the tissue damage marker AST; this correlation does not exist for patients lacking α Ep9 Abs (**Fig. S6A**). The sensitivity to IL-6 concentration before AST-monitored organ damage suggests anti-IL-6 therapeutics could be an effective management for α Ep9-positive patients (27, 38–40). Further investigation is required to examine the basis for ADE in α Ep9 patients.

Data presented here supports development of α Ep9 as a diagnostic test to predict severe disease (Odds Ratio = 5.525, 95% CI = 1.96, 15.59, **Fig 3B**). As shown here, α Ep9 Abs do not recognize orthologous sequences from closely related coronaviruses, providing good specificity for α Ep9 as a diagnostic. Previous studies have shown that the high homology of N protein among related coronaviruses can lead to high false positive rates in serodiagnostics with full-length N antigen (41).

Our analysis (n = 86) reveals that patients that test positive for the α Ep9 Abs are 3.17 times (Likelihood Ratio) more likely to have severe COVID-19 disease symptoms than patients that test negative for α Ep9 Abs. Since α Ep9 Abs appear early in the course

of disease, such a diagnostic could outperform traditional markers for the cytokine storm such as IL-6, which appears 6-8 days after symptom onset (27, 40); all plasma collected from α Ep9 positive patients ($n = 7$, **Fig 2C**) between 1 to 6 days post-symptoms onset demonstrate detectable levels of α Ep9 IgG (≥ 2 fold over negative control). Early detection of α Ep9 Abs in patients could be used to triage and treat COVID-19 prior to the onset of its most severe symptoms after which drugs can lose efficacy (27, 38–40) (**Fig. S6B**).

This study demonstrates the usefulness of fine epitope mapping, but the following limitations should be noted. Post-translational modifications, such as glycosylation were omitted for the phage-displayed S protein epitopes; COVAM antigens, however, are produced in baculovirus or HEK-293 cells, which could include glycans. Our analysis is based upon a population of 86 COVID-19 patients and 5 healthy patients, with the majority of Hispanic descent. The conclusions could be further strengthened with follow-up investigations in a larger population. Additionally, the population examined here only included three asymptomatic individuals, and additional testing is required to verify absence of α Ep9 Abs in such patients. The sample size of patients with multiple antibody targets was too limited to allow correlation analysis; future investigations could examine associations between α Ep9 and other Abs.

In summary, our investigation uncovers α Ep9 Abs as a potential early marker and predictor of disease severity in COVID-19 patients. The results presented here should be considered during development of vaccines that include N protein. Additionally, an evaluation of a patient's α Ep9 Abs and DRFS can provide a diagnostic triage for COVID-

19 disease monitoring and encourage preventative cytokine-related therapeutic interventions to mitigate disease severity.

Materials and Methods:

Detailed materials and methods for cloning, phage purification, patient sample collection, plasma phage-antibody ELISA, serum COVAM, and statistical analysis were described in the *Supplementary Materials*.

References and Notes:

1. World Health Organization, “Coronavirus Disease (COVID-19)” (2020).
2. A. Llanes, C. M. Restrepo, Z. Caballero, S. Rajeev, M. A. Kennedy, R. Lleonart, Betacoronavirus genomes: How genomic information has been used to deal with past outbreaks and the covid-19 pandemic. *Int. J. Mol. Sci.* **21**, 1–28 (2020).
3. S. Richardson, J. S. Hirsch, M. Narasimhan, J. M. Crawford, T. McGinn, K. W. Davidson, D. P. Barnaby, L. B. Becker, J. D. Chelico, S. L. Cohen, J. Cookingham, K. Coppa, M. A. Diefenbach, A. J. Dominello, J. Duer-Hefe, L. Falzon, J. Gitlin, N. Hajizadeh, T. G. Harvin, D. A. Hirschwerk, E. J. Kim, Z. M. Kozel, L. M. Marrast, J. N. Mogavero, G. A. Osorio, M. Qiui, T. P. Zanos, Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area. *J. Am. Med. Assoc.* **323**, 2052–2059 (2020).
4. B. Gallo Marin, G. Aghagoli, K. Lavine, L. Yang, E. J. Siff, S. S. Chiang, T. P. Salazar-Mather, L. Dumenco, M. C. Savaria, S. N. Aung, T. Flanigan, I. C. Michelow, Predictors of COVID-19 severity: A literature review. *Rev. Med. Virol.*

- (2020), doi:10.1002/rmv.2146.
5. P. Song, W. Li, J. Xie, Y. Hou, C. You, Cytokine storm induced by SARS-CoV-2. *Clin. Chim. Acta.* **509**, 280–287 (2020).
 6. W. S. Lee, A. K. Wheatley, S. J. Kent, B. J. DeKosky, Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. *Nat. Microbiol.* **5**, 1185–1191 (2020).
 7. B. S. Grahman, Vaccines Against Respiratory Syncytial Virus: The Time Has Finally Come. *Vaccine.* **34**, 3535–3541 (2016).
 8. A. M. Arvin, K. Fink, M. A. Schmid, A. Cathcart, R. Spreafico, C. Havenar-Daughton, A. Lanzavecchia, D. Corti, H. W. Virgin, A perspective on potential antibody-dependent enhancement of SARS-CoV-2. *Nature.* **584**, 353–363 (2020).
 9. L. R. Huang, C. M. Chiu, S. H. Yeh, W. H. Huang, P. R. Hsueh, W. Z. Yang, J. Y. Yang, I. J. Su, S. C. Chang, P. J. Chen, Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA. *J. Med. Virol.* **73**, 338–346 (2004).
 10. Y. He, Y. Zhou, P. Siddiqui, J. Niu, S. Jiang, Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. *J. Clin. Microbiol.* **43**, 3718–3726 (2005).
 11. Q. Long, B. Liu, H. Deng, G. Wu, K. Deng, Y. Chen, P. Liao, J. Qiu, Y. Lin, X. Cai, D. Wang, Y. Hu, J. Ren, N. Tang, Y. Xu, L. Yu, Z. Mo, F. Gong, X. Zhang, W. Tian, L. Hu, X. Zhang, J. Xiang, H. Du, H. Liu, C. Lang, X. Luo, S. Wu, X. Cui, Z. Zhou, M. Zhu, J. Wang, C. Xue, X. Li, L. Wang, Z. Li, K. Wang, C. Niu, Antibody responses to SARS-CoV-2 in patients with COVID-19, doi:10.1038/s41591-020-0897-1.

12. E. Fast, R. B. Altman, B. Chen, Potential T-cell and B-cell Epitopes of 2019-nCoV. **XXX**, 1–9 (2020).
13. A. Grifoni, J. Sidney, Y. Zhang, R. H. Scheuermann, B. Peters, A. Sette, A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. *Cell Host Microbe*. **27**, 671-680.e2 (2020).
14. V. Baruah, S. Bose, Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV. *J. Med. Virol.* **92**, 495–500 (2020).
15. M. Zheng, L. Song, Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. *Cell. Mol. Immunol.* **17**, 536–538 (2020).
16. B. Tilocca, A. Soggiu, M. Sanguinetti, V. Musella, D. Britti, L. Bonizzi, A. Urbani, P. Roncada, Comparative computational analysis of SARS-CoV-2 nucleocapsid protein epitopes in taxonomically related coronaviruses. *Microbes Infect.* **22**, 188–194 (2020).
17. A. Rakib, S. A. Sami, N. J. Mimi, M. M. Chowdhury, T. A. Eva, F. Nainu, A. Paul, A. Shahriar, A. M. Tareq, N. U. Emon, S. Chakraborty, S. Shil, S. J. Mily, T. Ben Hadda, F. A. Almalki, T. Bin Emran, Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein. *Comput. Biol. Med.* **124** (2020).
18. X. Liu, Y. Shi, P. Li, L. Li, Y. Yi, Q. Ma, C. Cao, Profile of Antibodies to the Nucleocapsid Protein of the Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus in Probable SARS Patients. *Clin. Diagn. Lab. Immunol.* **11**,

- 227–228 (2004).
19. P. N. Hedde, T. J. Abram, A. Jain, R. Nakajima, R. Ramiro de Assis, T. Pearce, A. Jasinskas, M. N. Toosky, S. Khan, P. L. Felgner, E. Gratton, W. Zhao, A modular microarray imaging system for highly specific COVID-19 antibody testing. *Lab Chip*. **20**, 3302–3309 (2020).
20. A. C. Walls, Y. J. Park, M. A. Tortorici, A. Wall, A. T. McGuire, D. Veessler, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell*. **181**, 281-292.e6 (2020).
21. J. Lan, J. Ge, J. Yu, S. Shan, H. Zhou, S. Fan, Q. Zhang, X. Shi, Q. Wang, L. Zhang, X. Wang, Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature*. **581**, 215–220 (2020).
22. W. Zheng, Y. Li, C. Zhang, R. Pearce, S. M. Mortuza, Y. Zhang, Deep-learning contact-map guided protein structure prediction in CASP13. *Proteins Struct. Funct. Bioinforma*. **87**, 1149–1164 (2019).
23. W. Tian, W. Jiang, J. Yao, C. J. Nicholson, R. H. Li, H. H. Sigurslid, L. Wooster, J. I. Rotter, X. Guo, R. Malhotra, Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. *J. Med. Virol.* **92**, 1875–1883 (2020).
24. A. Simonnet, M. Chetboun, J. Poissy, V. Raverdy, J. Noulette, A. Duhamel, J. Labreuche, D. Mathieu, F. Pattou, M. Jourdain, R. Caizzo, M. Caplan, N. Cousin, T. Duburcq, A. Durand, A. El kalioubie, R. Favory, B. Garcia, P. Girardie, J. Goutay, M. Houard, E. Jaillette, N. Kostuj, G. Ledoux, D. Mathieu, A. S. Moreau, C. Niles, S. Nseir, T. Onimus, E. Parmentier, S. Préau, L. Robriquet, A. Rouze, S. Six, H.

Verkindt, High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. *Obesity*. **28**, 1195–1199 (2020).

25. L. Y. W. Lee, J. B. Cazier, T. Starkey, S. E. W. Briggs, R. Arnold, V. Bisht, S. Booth, N. A. Campton, V. W. T. Cheng, G. Collins, H. M. Curley, P. Earwaker, M. W. Fittall, S. Gennatas, A. Goel, S. Hartley, D. J. Hughes, D. Kerr, A. J. X. Lee, R. J. Lee, S. M. Lee, H. Mckenzie, C. P. Middleton, N. Murugaesu, T. Newsom-Davis, A. C. Olsson-Brown, C. Palles, T. Powles, E. A. Protheroe, K. Purshouse, A. Sharma-Oates, S. Sivakumar, A. J. Smith, O. Topping, C. D. Turnbull, C. Várnai, A. D. M. Briggs, G. Middleton, R. Kerr, A. Gault, M. Agnieszka, A. Bedair, A. Ghaus, A. Akingboye, A. Maynard, A. Pawsey, A. A. Mohamed, A. Okines, A. Massey, A. Kwan, A. Ferreira, A. Angelakas, A. Wu, A. Tivey, A. Armstrong, A. Madhan, A. Pillai, A. Poon-King, B. Kurec, C. Usborne, C. Dobeson, C. Thirlwell, C. Mitchell, C. Sng, C. Scrase, C. Jingree, C. Brunner, C. Fuller, C. Griffin, C. Barrington, D. Muller, D. Ottaviani, D. Gilbert, E. Tacconi, E. Copson, E. Renninson, E. Cattell, E. Burke, F. Smith, F. Holt, G. Soosaipillai, H. Boyce, H. Shaw, H. Hollis, H. Bowyer, I. Anil, J. Illingworth, J. Gibson, J. Bhosle, J. Best, J. Barrett, J. Noble, J. Sacco, J. Chacko, J. Chackathayil, K. Banfill, L. Feeney, L. Horsley, L. Cammaert, L. Mukherjee, L. Eastlake, L. Devereaux, L. Melcher, L. Cook, M. Teng, M. Hewish, M. Bhattacharyya, M. Choudhury, M. Baxter, M. Scott-Brown, M. Fittall, M. Tilby, M. Rowe, M. Alihilali, M. Galazi, N. Yousaf, N. Chopra, N. Cox, O. Chan, O. Sheikh, P. Ramage, P. Greaves, P. Leonard, P. S. Hall, P. Naksukpaiboon, P. Corrie, R. Peck, R. Sharkey, R. Bolton, R. Sargent, R. Jyothirmayi, R. Goldstein, R. Oakes,

- R. Shotton, R. Kanani, R. Board, R. Pettengell, R. Claydon, S. Moody, S. Massalha, S. Kathirgamakarthisgeyan, S. Dolly, S. Derby, S. Lowndes, S. Benafif, S. Eeckelaers, S. Kingdon, S. Ayers, S. Brown, S. Ellis, S. Parikh, S. Pugh, S. Shamas, S. Wyatt, S. Grumett, S. Lau, Y. N. S. Wong, S. McGrath, S. Cornthwaite, S. Hibbs, T. Tillet, T. Rabbi, T. Robinson, T. Roques, V. Angelis, V. Woodcock, V. Brown, Y. Y. Peng, Y. Drew, Z. Hudson, COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. *Lancet Oncol.*, 1309–1316 (2020).
26. M. E. Charlson, P. Pompei, K. L. Ales, C. R. MacKenzie, A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *J. Chronic Dis.* **40**, 373–383 (1987).
27. L. Lu, H. Zhang, M. Zhan, J. Jiang, H. Yin, D. J. Dauphars, S. Y. Li, Y. Li, Y. W. He, Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm? *Front. Cell Dev. Biol.* **8**, 1–10 (2020).
28. M. J. Cummings, M. R. Baldwin, D. Abrams, S. D. Jacobson, B. J. Meyer, E. M. Balough, J. G. Aaron, J. Claassen, L. R. E. Rabbani, J. Hastie, B. R. Hochman, J. Salazar-Schicchi, N. H. Yip, D. Brodie, M. R. O'Donnell, Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet.* **395**, 1763–1770 (2020).
29. Y. Yang, C. Shen, J. Li, J. Yuan, J. Wei, F. Huang, F. Wang, G. Li, Y. Li, L. Xing, L. Peng, M. Yang, M. Cao, H. Zheng, W. Wu, R. Zou, D. Li, Z. Xu, H. Wang, M. Zhang, Z. Zhang, G. F. Gao, C. Jiang, L. Liu, Y. Liu, Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19.

- J. Allergy Clin. Immunol.* **146**, 119-127.e4 (2020).
30. H. wei Jiang, Y. Li, H. nan Zhang, W. Wang, X. Yang, H. Qi, H. Li, D. Men, J. Zhou, S. ce Tao, SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses. *Nat. Commun.* **11** (2020).
 31. M. Batra, R. Tian, C. Zhang, E. Clarence, C. Sofia Sacher, J. Nestor Miranda, J. O. Rafa De La Fuente, M. Mathew, D. Green, S. Patel, M. Virginia Perez Bastidas, S. Haddadi, M. Murthi, M. Santiago Gonzalez, S. Kambali, K. H. M Santos, H. Asif, F. Modarresi, M. Faghihi, M. Mirsaeidi, *medRxiv*, in press.
 32. W. Tan, Y. Lu, J. Zhang, J. Wang, Y. Dan, Z. Tan, X. He, C. Qian, Q. Sun, Q. Hu, H. Liu, S. Ye, X. Xiang, Y. Zhou, W. Zhang, Y. Guo, X.-H. Wang, W. He, X. Wan, F. Sun, Q. Wei, C. Chen, G. Pan, J. Xia, Q. Mao, Y. Chen, G. Deng, Viral Kinetics and Antibody Responses in Patients with COVID-19 (2020).
 33. L. Wang, J. Candia, L. Ma, Y. Zhao, L. Imberti, A. Sottini, K. Dobbs, NIAID-NCI COVID Consortium, A. Lisco, I. Sereti, H. C. Su, L. D. Notarangelo, X. W. Wang, Serological Responses to Human Virome Define Clinical Outcomes of Italian Patients Infected with SARS-CoV-2. *medRxiv* (2020).
 34. C. R. Zamecnik, J. V. Rajan, K. A. Yamauchi, S. A. Mann, R. P. Loudermilk, G. M. Sowa, K. C. Zorn, B. D. Alvarenga, C. Gaebler, M. Caskey, M. Stone, P. J. Norris, W. Gu, C. Y. Chiu, D. Ng, J. R. Byrnes, X. X. Zhou, J. A. Wells, D. F. Robbani, M. C. Nussenzweig, J. L. DeRisi, M. R. Wilson, ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens. *Cell Rep Med* (2020).
 35. Q. X. Long, B. Z. Liu, H. J. Deng, G. C. Wu, K. Deng, Y. K. Chen, P. Liao, J. F. Qiu, Y. Lin, X. F. Cai, D. Q. Wang, Y. Hu, J. H. Ren, N. Tang, Y. Y. Xu, L. H. Yu, Z. Mo,

- F. Gong, X. L. Zhang, W. G. Tian, L. Hu, X. X. Zhang, J. L. Xiang, H. X. Du, H. W. Liu, C. H. Lang, X. H. Luo, S. B. Wu, X. P. Cui, Z. Zhou, M. M. Zhu, J. Wang, C. J. Xue, X. F. Li, L. Wang, Z. J. Li, K. Wang, C. C. Niu, Q. J. Yang, X. J. Tang, Y. Zhang, X. M. Liu, J. J. Li, D. C. Zhang, F. Zhang, P. Liu, J. Yuan, Q. Li, J. L. Hu, J. Chen, A. L. Huang, Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat. Med.* **26**, 845–848 (2020).
36. A. Iwasaki, Y. Yang, The potential danger of suboptimal antibody responses in COVID-19. *Nat. Rev. Immunol.* **20**, 339–341 (2020).
37. T. Chareonsirisuthigul, S. Kalayanaroj, S. Ubol, Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. *J. Gen. Virol.* **88**, 365–375 (2007).
38. M. Benucci, G. Giannasi, P. Cecchini, F. L. Gobbi, A. Damiani, V. Grossi, M. Infantino, M. Manfredi, COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients. *J. Med. Virol.* **92**, 2368–2370 (2020).
39. J. P. Knorr, V. Colomy, C. M. Mauriello, S. Ha, Tocilizumab in patients with severe COVID-19: A single-center observational analysis. *J. Med. Virol.*, in press.
40. A. Langer-Gould, J. B. Smith, E. G. Gonzales, R. D. Castillo, J. Garza Figueroa, A. Ramanathan, B. H. Li, M. K. Gould, Early Identification of COVID-19 Cytokine Storm and Treatment with Anakinra or Tocilizumab. *Int. J. Infect. Dis.* **99**, 291–297 (2020).
41. Y. Yamaoka, S. S. Jeremiah, K. Miyakawa, R. Saji, M. Nishii, I. Takeuchi, A. Ryo, Whole Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus

- 2 May Cause False-Positive Results in Serological Assays. *Clin. Infect. Dis.* (2020).
42. K. Murase, K. L. Morrison, P. Y. Tam, R. L. Stafford, F. Journak, G. A. Weiss, EF-Tu binding peptides identified, dissected, and affinity optimized by phage display. *Chem. Biol.* **10**, 161–168 (2003).
43. A. Bhasin, E. C. Sanders, J. M. Ziegler, J. S. Briggs, N. P. Drago, A. M. Attar, A. M. Santos, M. Y. True, A. F. Ogata, D. V. Yoon, S. Majumdar, A. J. Wheat, S. V. Patterson, G. A. Weiss, R. M. Penner, Virus Bioresistor (VBR) for Detection of Bladder Cancer Marker DJ-1 in Urine at 10 pM in One Minute. *Anal. Chem.* **92**, 6654–6666 (2020).
44. B. Pastorino, F. Touret, M. Gilles, X. De Lamballerie, R. N. Charrel, Heat Inactivation of Different Types of SARS-CoV-2 Samples: What Protocols for Biosafety, Molecular Detection and Serological Diagnostics? *Viruses*. **12**, 1–8 (2020).
45. S. Khan, A. Jain, O. Taghavian, R. Nakajima, A. Jasinskas, M. Supnet, J. Felgner, J. Davies, R. R. de Assis, S. Jan, J. Obiero, E. Strahsburger, E. J. Pone, L. Liang, D. H. Davies, P. L. Felgner, Use of an influenza antigen microarray to measure the breadth of serum antibodies across virus subtypes. *J. Vis. Exp.* **2019**, 1–8 (2019).
46. A. Jain, O. Taghavian, D. Vallejo, E. Dotsey, D. Schwartz, F. G. Bell, C. Greef, D. H. Davies¹, J. Grudzien, A. P. Lee, P. Felgner, L. Liang, Evaluation of Quantum dot immunofluorescence and a digital CMOS imaging system as an alternative to conventional organic fluorescence dyes and laser scanning for quantifying protein microarrays. *Proteomics*. **16**, 1271–1279 (2016).
47. R. Nakajima, M. Supnet, A. Jasinskas, A. Jain, O. Taghavian, J. Obiero, D. K.

- Milton, W. H. Chen, M. Grantham, R. Webby, F. Krammer, D. Carter, P. L. Felgner, D. H. Davies, Protein Microarray Analysis of the Specificity and Cross-Reactivity of Influenza Virus Hemagglutinin-Specific Antibodies. *mSphere*. **3**, 1–15 (2018).
48. M. M. Mukaka, Statistics Corner: A guide to appropriate use of Correlation coefficient in medical research. *Malawi Med J*. **24**, 69-71 (2012).
49. B. Korber, W. M. Fischer, S. Gnanakaran, H. Yoon, J. Theiler, W. Abfalterer, N. Hengartner, E. E. Giorgi, T. Bhattacharya, B. Foley, K. M. Hastie, M. D. Parker, D. G. Partridge, C. M. Evans, T. M. Freeman, T. I. de Silva, A. Angyal, R. L. Brown, L. Carrilero, L. R. Green, D. C. Groves, K. J. Johnson, A. J. Keeley, B. B. Lindsey, P. J. Parsons, M. Raza, S. Rowland-Jones, N. Smith, R. M. Tucker, D. Wang, M. D. Wyles, C. McDanal, L. G. Perez, H. Tang, A. Moon-Walker, S. P. Whelan, C. C. LaBranche, E. O. Saphire, D. C. Montefiori, Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. *Cell*. **182**, 812-827 (2020).

Author Information:

Corresponding Author:

*GAW e-mail: gweiss@uci.edu, Tel: +1-949-824-5566.

ORCID

S Sen: 0000-0002-1535-814X
 EC Sanders: 0000-0003-1043-5772
 KN Gabriel: 0000-0002-9518-0483
 BM Miller: 0000-0001-9186-3706
 HM Isoda: 0000-0003-0724-0667
 GS Salcedo: 0000-0002-9794-3894
 JE Garrido: 0000-0003-0741-8672
 RP Dyer: 0000-0001-5407-3561
 R Nakajima: 0000-0002-1986-9086
 A Jain: 0000-0002-9536-0097

AM Santos: 0000-0002-0887-2140
 K Bhuvan: 0000-0001-8760-2570
 DF Tifrea: 0000-0002-7531-9337
 JL Ricks-Oddie: 0000-0002-9305-7692
 PL Felgner: 0000-0002-4117-8505
 RA Edwards: 0000-0001-9145-382X
 S Majumdar: 0000-0001-6738-2267
 GA Weiss: 0000-0003-0296-9846

Acknowledgements: We gratefully acknowledge the support of the UCI COVID-19 Basic, Translational and Clinical Research Fund (CRAFT), the NIH funded California Breast Cancer Research Program (R00RG2519), and the Public Impact Fellowship from the UCI Graduate Division. This study was also sponsored by Allergan (prior to its acquisition by AbbVie). K.N.G. was supported by a National Science Foundation Graduate Research Fellowship Program (DGE-1839285). G.S.S and A.M.S thank the Minority Access to Research Careers (MARC) Program, funded by the NIH (GM-69337). J.L.R was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences from the NIH (TR001414). D.F.T and R.A.E. were supported by the Experimental Tissue Resource, funded by the Chao Family NCI-Comprehensive Cancer Center Support Grant from the NCI (P30CA062203). **Author Contributions:** S.S., E.C.S., K.N.G., S.M., P.L.F., and G.A.W. designed research; S.S., E.C.S., K.N.G., B.M.M., H.M.I., G.S.S., J.E.G., R.P.D., A.M.S., K.B., R.N., and A.J. performed research; S.S., E.C.S. and K.N.G. analyzed data; J.L.R. advised on statistical analysis; D.F.T. and R.A.E. collected patient samples and advised on patient clinical data analysis; and S.S., E.C.S., K.N.G., S.M., and G.A.W. wrote the manuscript. **Competing interests:** The authors declare the following competing financial interest(s): P.L.F., R.N., and A.J. have a financial interest in a company, Nanommune Inc., that is commercializing

the COVAM technology. Nanommune partners with Sino Biological Inc. (Beijing, China) for expression and purification of COVAM antigens used in this study. The terms of this arrangement have been reviewed and approved by the University of California, Irvine in accordance with its conflict of interest policies. **Data and materials availability:** All data that support the conclusions of the study are available from the corresponding author upon request.

Supplementary Materials: General methods and additional experimental data can be found in the *Supplementary Materials*.

Figs. S1 to S7

Tables S1 to S4

References (42–49)